Eltrombopag action and efficacy

Eltrombopagis a thrombopoietin receptor agonist, suitable for:

1.Indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP)1 years of age and older who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy.

2.Eltrombopag is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C who may receive interferon-based initial or maintenance therapy.

3.Indicated in the first-line treatment of adults and children 2 years old and above in combination with standard immunosuppressive therapy.

Usage restrictions:

Eltrombopagis not indicated for the treatment of patients with myelodysplastic syndrome(MDS).

The safety and effectiveness of concomitant use with interferon-free direct-acting antivirals for the treatment of chronic hepatitis C infection have not been established.

Eltrombopag is a TPO receptor agonist that interacts with the transmembrane region of the human TPO receptor ( also known as cMpl) and initiates a signaling cascade that induces megakaryocyte proliferation and differentiation, leading to increased platelet production. In clinical trials, treatment with eltrombopag resulted in dose-dependent increases in platelet counts following repeated (daily) dosing. Increases in platelet counts were maximal approximately two weeks after initiation of dosing and returned to baseline levels approximately two weeks after the last dose of eltrombopag. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.